Document Detail

Effects of prostaglandin E2 on disease activity, gastric secretion and intestinal permeability, and morphology in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  3166369     Owner:  NLM     Status:  MEDLINE    
The effects of oral natural prostaglandin E2 (PGE2) on symptoms, disease activity, and gastrointestinal functions in rheumatoid arthritis (RA) were studied in an open pilot trial. Twelve patients, six taking and six not taking non-steroidal anti-inflammatory drugs (NSAIDs), received 1 mg natural PGE2 three times a day for six weeks. The treatment was tolerated well and the only side effect noted was slightly looser stools in three patients. Half of the patients reported subjective improvement and none had aggravation of symptoms. The Ritchie articular index and several biochemical inflammation markers decreased and were significantly reduced at the end of the treatment period. The thickness of the small intestinal mucosa increased during the PGE2 treatment. The intestinal permeability pattern, measured by urinary excretion of polyethylene glycols (PEG 400), differed between the patients taking and not taking NSAIDs. The initially high urinary PEG 400 excretion values in the patients taking NSAIDs decreased and the initially low excretion values in patients not taking NSAIDs increased during the PGE2 treatment. The jejunal contents became sterile in 5/6 patients not taking NSAIDs and remained sterile in 1/6 patients taking NSAIDs at the end of the treatment. The treatment period was associated with a reduction of lactobacilli in patients not treated with NSAIDs. Thus the treatment appeared to decrease disease activity and to improve small intestinal functions in patients with RA, findings that need confirmation in a controlled trial.
A E Henriksson; C Tagesson; A Uribe; K Uvnäs-Moberg; C E Nord; R Gullberg; C Johansson
Related Documents :
8572739 - Expression of rheumatoid arthritis in two ethnic jewish israeli groups.
15108069 - Bone mineral density and urolithiasis interaction in rheumatoid arthritis.
1676079 - In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 o...
12945719 - Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
16572449 - Evaluation of classical complement pathway activation in rheumatoid arthritis: measurem...
3743149 - Reappraisal of respiratory abnormalities in primary and secondary sjögren's syndrome. a...
21481739 - Cortical tubers, cognition, and epilepsy in tuberous sclerosis.
17951889 - The new israeli law on the care of the terminally ill: conceptual innovations waiting f...
336239 - Discrete membranous subaortic stenosis. report of 31 patients, review of the literature...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  47     ISSN:  0003-4967     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  1988 Aug 
Date Detail:
Created Date:  1988-10-11     Completed Date:  1988-10-11     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  620-7     Citation Subset:  IM    
Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Arthritis, Rheumatoid / drug therapy*,  metabolism,  microbiology,  pathology
Bacteria / isolation & purification
Gastric Acid / secretion*
Gastric Juice / microbiology
Intestinal Absorption / drug effects*
Intestinal Mucosa / pathology*
Jejunum / microbiology
Middle Aged
Prostaglandins E / therapeutic use*
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Prostaglandins E; 363-24-6/Dinoprostone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a nove...
Next Document:  Fatal cerebral toxoplasmosis in a leukemia child in remission